Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Newer progestogens.

¹South East Hertfordshire Primary Care Trust, Health Centre, Hitchin, Herts, UK. dr.rowlands@lister.enherts-tr.nhs.uk

The Journal of Family Planning and Reproductive Health Care

|March 11, 2003

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Would it be feasible for European Union countries to implement Safe Access Zones for premises providing abortion services?

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2025

Same author

Mandatory spousal authorisation for abortion: characteristics of countries in which it exists and the potential for modernisation of the law.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2024

Same author

Psychosocial Aspects of the Lived Experience of Long COVID: A Systematic Review and Thematic Synthesis of Qualitative Studies.

Health expectations : an international journal of public participation in health care and health policy·2024

Same author

Celebrating 50 years of our Journal.

BMJ sexual & reproductive health·2024

Same author

Improving access to medicines for early medical abortion: learning from experiences of medicines licensing and service delivery.

BMJ sexual & reproductive health·2023

Same author

How to recognise and respond to reproductive coercion.

BMJ (Clinical research ed.)·2022

Same journal

Venus.

The journal of family planning and reproductive health care·2017

Same journal

Elizabeth (Libby) Wilson 1926-2016.

The journal of family planning and reproductive health care·2017

Same journal

Venting grief for vocational erosion.

The journal of family planning and reproductive health care·2017

Same journal

A chemsex crucible: the context and the controversy.

The journal of family planning and reproductive health care·2017

Same journal

Sex, drugs and self-control: why chemsex is fast becoming a public health concern.

The journal of family planning and reproductive health care·2017

Same journal

A very specific absence of focus? A patient's response to 'Diagnosing migraine'.

The journal of family planning and reproductive health care·2017

See all related articles

Newer progestogens offer improved tolerability in contraceptives due to lacking androgenic activity. These advanced compounds, including dienogest and drospirenone, show similar efficacy to older options.

Area of Science:

Reproductive endocrinology
Pharmacology
Contraceptive development

Background:

Recent advancements in progestogen development are crucial for improving contraceptive options.
Understanding the clinical profiles of new progestogens is essential for patient care.

Purpose of the Study:

To review newly developed progestogens.
To compare their clinical profiles with older progestogens.
To evaluate the potential of unmarketed progestogen-containing products.

Main Methods:

Literature search of Medline and Popline databases.
Analysis of technical papers for metabolic and receptor binding characteristics.
Examination of clinical trials for efficacy, bleeding patterns, and tolerability, prioritizing comparative studies.

Related Experiment Videos

Main Results:

Five new progestogens have been developed; all lack androgenic activity, with some possessing antiandrogenic properties.
Combined oral contraceptives (COCs) with dienogest and drospirenone are available.
Nomegestrol and nestorone show promise in subdermal implant formulations.

Conclusions:

Newer progestogens in combined hormonal contraceptives exhibit similar performance to existing products.
Progestogen-only contraceptives utilizing novel progestogens may offer enhanced tolerability due to the absence of androgenic effects.